Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 7 8 9 10 11 … 50 Next »

Cosentyx V Stelara 52 week efficacy and safety study

Threaded Mode
Cosentyx V Stelara 52 week efficacy and safety study
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 59,567
Threads: 3,623
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 3
Psoriatic Arthritis Score: 3
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Tue-05-05-2020, 16:01 PM
Results of a 52 week efficacy and safety study of Cosentyx v Stelara

Quote:
Background:
Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study.

Objective:
To compare the efficacy and safety of secukinumab vs ustekinumab over 52 weeks in CLARITY.

Methods:
Analysis of 52‐week data from CLARITY (NCT02826603), a phase 3b study in which patients were randomized to receive secukinumab 300 mg (n = 550) or ustekinumab 45/90 mg (n = 552) per label.

Results:
At week 52, secukinumab was superior to ustekinumab in the proportion of patients who achieved ≥90% improvement in Psoriasis Area and Severity Index (73.2% vs 59.8%; odds ratio [OR], 1.84 [95% CI, 1.41‐2.41]; P < .0001), Investigator’s Global Assessment modified 2011 responses of clear (0) or almost clear (1) skin (76.0% vs 60.2%; OR, 2.12 [95% CI, 1.61‐2.79]; P < .0001), and Dermatology Life Quality Index response of no effect (0/1) (69.9% vs 61.2%; P = .0028). Proportions of patients with any adverse events were comparable between treatment arms.

Conclusions:
This second head‐to‐head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Cosentyx (secukinumab)

Stelara (ustekinumab)
Quote
Caroline Offline
You must hurry if you ever want to catch a chicken...
*
Forum Helper
Posts: 23,025
Threads: 108
Joined: Nov 2011
Gender: Female
Location: In between the tulips
Psoriasis Score: 3
Psoriatic Arthritis Score: 3
PQOLS: 4
Treatment: Got back to DMF slow release
#2
Sun-17-05-2020, 21:15 PM
The star of Cosentyx keeps on rising. Smile

But ... I still cannot read the statistics that are contained in the research... very annoying.

So... I bought a book of a well known Dutch teacher, who was formerly knows as one of the math girls. She, Ionica, is a professor in mathematics now and knows everything about statistics. So I am reading that first and now are beginning to realise that numbers in statistics are very difficult to interpret. It contains rules that are not obvious.
I may (not will) give an example later on. It is a very readable book, but that is because it is in Dutch. Rolleyes

I also found an old and very large book called “Statistics” by Shaum. It is an ugly purple softcover book, but... it looks very professional. Now finding the time to study it. Whistle
Quote
jiml Offline
Forum Helper
*
Forum Helper
Posts: 47,973
Threads: 357
Joined: Oct 2013
Gender: Male
Location: Norwich England
Psoriasis Score: 3
Treatment: Skilarence 5x120mg a day
#3
Sun-17-05-2020, 21:34 PM
You have more patience than me Caroline Statistics is a difficult subject Clap
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Taiwan study on infections in psoriasis patients Fred 4 676 Sat-26-08-2023, 11:15 AM
Last Post: Fred
News Stelara vs Tremfya German study Fred 1 474 Thu-20-07-2023, 07:24 AM
Last Post: Caroline
News Izokibep and psoriatic arthritis 46 week data Fred 0 746 Tue-11-04-2023, 13:35 PM
Last Post: Fred
News Cosentyx efficacy, safety and tolerability in children with psoriasis Fred 0 733 Sat-08-04-2023, 11:57 AM
Last Post: Fred
News Psoriasis and cardiovascular study Fred 2 1,383 Fri-24-03-2023, 21:41 PM
Last Post: Kat



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode